Temporal relationship of first-episode non-affective psychosis with cannabis use: A clinical verification of an epidemiological hypothesis

Journal of Psychiatric Research

Volumn 44, Issue 7, 2010, Pages 413-420

  Barrigón, María L ^a,b   Gurpegui, Manuel ^a   Ruiz Veguilla, Miguel ^a,c   Diaz, Francisco J ^d   Anguita, Manuel ^e   Sarramea, Fernando ^c   Cervilla, Jorge ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Hospital Santa Ana   (Spain)

^c Jaén Medical Center   (Spain)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Cannabis; Cocaine; Drug use; First episode psychosis; Psychosis onset; Schizophrenia

Indexed keywords

COCAINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BRIEF PSYCHOTIC DISORDER; CANNABIS SMOKING; CONTROLLED STUDY; DELUSIONAL DISORDER; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; EDUCATION; EFFECT SIZE; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER;

EID: 77952887777     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.10.004     Document Type: Article

References (53)

1. Aleman A., Kahn R.S., Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Archives of General Psychiatry 2003, 60:565-571.
2. Arendt M., Rosenberg R., Foldager L., Perto G., Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry 2005, 187:510-515.
3. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 2002, 325:1212-1213.
4. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 2004, 184:110-117.
5. Ashtari M., Cervellione K., Cottone J., Ardekani B.A., Kumra S. Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use. Journal of Psychiatry Research 2009, 43:189-204.
6. Barnes T.R., Mutsatsa S.H., Hutton S.B., Watt H.C., Joyce E.M. Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry 2006, 188:237-242.
7. Barnett J.H., Werners U., Secher S.M., Hill K.E., Brazil R., Masson K., et al. Substance use in a population-based clinic sample of people with first-episode psychosis. British Journal of Psychiatry 2007, 190:515-520.
8. Brady K.T., Lydiard R.B., Malcolm R., Ballenger J.C. Cocaine-induced psychosis. Journal of Clinical Psychiatry 1991, 52:509-512.
9. Bühler B., Hambrecht M., Löffler W., an der Heiden W., Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 2002, 54:243-251.
10. Cantor-Graae E., Nordstrøm L.G., McNeil T.F. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophrenia Research 2001, 48:69-82.
11. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry 2001, 15:71-83.
12. Chen C.K., Lin S.K., Sham P.C., Ball D., Loh E.W., Hsiao C.C., et al. Premorbid characteristics and comorbidity of methamphetamine users with and without psychosis. Psychological Medicine 2003, 33:1407-1414.
13. Cougnard A., Marcelis M., Myin-Germeys I., De Graaf R., Vollebergh W., Krabbendam L., et al. Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychological Medicine 2007, 37:513-527.
14. Cubells J.F., Feinn R., Pearson D., Burda J., Tang Y., Farrer L.A., et al. Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the scale for assessment of positive symptoms for cocaine-induced psychosis (SAPS-CIP). Drug and Alcohol Dependence 2005, 80:23-33.
15. Curran C., Byrappa N., McBride A. Stimulant psychosis: systematic review. British Journal of Psychiatry 2004, 185:196-204.
16. Degenhardt L., Tennant C., Gilmour C., Gilmour S., Schofield D., Nash L., et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological Medicine 2007, 37:927-934.
17. D'Souza C., Cho H.S., Perry E.B., Krystal J.H. A cannabinoid model psychosis, dopamine-cannabinoid interactions and implications for schizophrenia. Marijuana and madness 2004, 142-166. Cambridge University Press, Cambridge. J.D. Castle, R. Murray (Eds.).
18. European Monitoring Centre for Drugs and Drug Addiction. The state of the drugs problem in Europe. Annual report 2006. Available from: http://ar2006.emcdda.europa.eu/download/ar2006-en.pdf.
19. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSMIV axis I disorders (clinician version) 1997, American Psychiatric Association, Washington. 1st ed.
20. Floyd A.G., Boutros N.N., Struve F.A., Wolf E., Oliwa G.M. Risk factors for experiencing psychosis during cocaine use: a preliminary report. Journal of Psychiatry Research 2006, 40:178-182.
21. González-Pinto A., Vega P., Ibáñez B., Mosquera F., Barbeito S., Gutiérrez M., et al. Impact of cannabis and other drugs on age at onset of psychosis. Journal of Clinical Psychiatry 2008, 69:1210-1216.
22. Gorriti M.A., Rodriguez de Fonseca F., Navarro M., Palomo T. Chronic delta (9)-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. European Journal of Pharmacology 1999, 365:133-1342.
23. Green A.I., Tohen M.F., Hamer R.M., Strakowski S.M., Lieberman J.A., Glick I., et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research 2004, 66:125-135.
24. Hambrecht M., Häfner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry 1996, 40:1155-1163.
25. Hambrecht M., Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Australian and New Zealand Journal of Psychiatry 2000, 34:468-475.
26. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 2005, 31:608-612.
27. Kavanagh D.J., Waghorn G., Jenner L., Chant D.C., Carr V., Evans M., et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research 2004, 66:115-124.
28. Klein J.P., Moeschberger M.L. Survival analysis. Techniques for censored and truncated data 1997, Springer, New York.
29. Konings M., Henquet C., Maharajh H.D., Hutchinson G., Van Os J. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatrica Scandinavica 2008, 118:209-213.
30. Lamarque S., Taghzouti K., Simon H. Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001, 41:118-129.
31. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica Supplementum 2000, 401:S3-S38.
32. Loranger A.W. Sex difference in age at onset of schizophrenia. Archives of General Psychiatry 1984, 41:157-161.
33. Martínez-Ortega J.M., Jurado D., Gurpegui M. Nicotine dependence vs. daily smoking as a meaningful variable: implications for clinical and epidemiological psychiatric studies. Progress in Neuro-psychopharmacology and Biological Psychiatry 2008, 32:1972-1977.
34. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
35. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
36. Norman R.M., Malla A.K. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychological Medicine 2001, 31:381-400.
37. Post R.M. Cocaine psychoses: a continuum model. American Journal of Psychiatry 1975, 132:225-231.
38. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA 1990, 264:2511-2518.
39. Ruiz-Veguilla M., Gurpegui M., Barrigón M.L., Ferrín M., Marín E., Rubio J.L., et al. Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use. Schizophrenia Research 2009, 107:158-164.
40. Satel S.L., Edell W.S. Cocaine-induced paranoia and psychosis proneness. American Journal of Psychiatry 1991, 148:1708-1711.
41. Semple D.M., McIntosh A.M., Lawrie S.M. Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 2005, 19:187-194.
42. Sevy S., Robinson D.G., Holloway S., Alvir J.M., Woerner M.G., Bilder R., et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica 2001, 104:367-374.
43. SPSS Inc. SPSS advanced models 12.0. Chicago, USA: SPSS Inc.; 2003.
44. Stefanis N.C., Delespaul P., Henquet C., Bakoula C., Stefanis C.N., Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004, 99:1333-1341.
45. Sugranyes G., Flamarique I., Parellada E., Baeza I., Goti J., Fernandez-Egea E., et al. Cannabis use and age of diagnosis of schizophrenia. European Psychiatry 2009, 24:282-286.
46. van Nimwegen L., de Haan L., van Beveren N., van den Brink W., Linszen D. Adolescence, schizophrenia and drug abuse: a window of vulnerability. Acta Psychiatrica Scandinavica 2005, 427:S35-S42.
47. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 2002, 156:319-327.
48. Veen N.D., Selten J.P., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry 2004, 161:501-506.
49. Viveros M.P., Llorente R., Moreno E., Marco E.M. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behavioural Pharmacology 2005, 16:353-362.
50. Weaver T., Madden P., Charles V., Stimson G., Renton A., Tyrer P., et al. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. British Journal of Psychiatry 2003, 183:304-313.
51. Wilson W., Mathew R., Turkington T., Hawk T., Coleman R.E., Provenzale J. Brain. Morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. Journal of Addictive Diseases 2000, 19:1-22.
52. Woodward M. Epidemiology. Study design and data analysis 1999, Chapman and Hall/CRC, Boca Raton, FL. 1st ed.
53. World Health Organization. Composite international diagnostic interview (CIDI), version 1.1. Geneva, Switzerland; 1993.